Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap-Reference-Cited by-同舟云学术

Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap

Published:2021-08 Issue: Volume:Volume 15 Page:3391-3409
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Conti Nicolina^ORCID,Gatti Milo,Raschi Emanuel^ORCID,Diemberger Igor,Potena Luciano

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference82 articles.

1. Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use

2. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis

3. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial

4. European Medicines Agency. EU/3/18/1980. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3181980. Accessed March 29, 2021.

5. Potential of the Cardiovascular Drug Levosimendan in the Management of Amyotrophic Lateral Sclerosis

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful Use of Levosimendan in Managing Refractory Coronary Vasospasm Leading to Recurrent Cardiac Arrests: A Case Report;2024-07-18

2. Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes;Journal of Clinical Medicine;2024-07-14

3. The therapeutic effect of levosimendan in patients with prolonged ventilator weaning and cardiac dysfunction;Journal of International Medical Research;2024-07

4. Challenging and target-based shifting strategies for heart failure treatment: An update from the last decades;Biochemical Pharmacology;2024-06

5. Reorganization of the actin cytoskeleton during the formation of neutrophil extracellular traps (NETs);European Journal of Cell Biology;2024-06